Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 ...

Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy) data in adults with relapsing forms of multiple sclerosis (RMS) ...

Chronic hepatitis delta virus (HDV) infection has its first FDA-approved treatment, after the agency granted accelerated approval to bulevirtide (Hepcludex) injection for adults without cirrhosis or ...

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial ...

Most people who get the hepatitis B vaccine have protection for their whole life. People on dialysis or those who don't respond to the vaccine might need a booster. Some vaccines work faster and may ...

FDA regulatory momentum includes priority review and breakthrough therapy designation for a potential first-in-class CHB functional cure, with a PDUFA target date of October 26, 2026. Current ...

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus ...

Primary endpoint (virologic response and ALT normalization) achieved in both dose arms at Week 24 -Favorable safety and tolerability profiles observed - Full results to be presented in a late-breaking ...

DNA-HBVac was generated based on the pVAX plasmid (Invitrogen, Karlsruhe, Germany). It contains cytomegalovirus (CMV) immediate early (IE) promoter (CMV-IE), followed by the R region from human T cell ...

A multinational Hepatitis B and HIV Cure Consortium led by Johns Hopkins Medicine was recently established with the awarding of a five-year, $24 million grant from the National Institutes of Health's ...

Researchers retrospectively assessed the decline of anti-HBs level in vaccinated people with HIV-1 infection using data from the French national database between October 1988 and March 2024. They ...